Carter T. Fields

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Carter Fields
Publication record
15 papers · 1,752 citations · H-index 8

PAPERS

The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
202435 citationsauthor #5
Abstract 1207: Preclinical development of 2nd generation HER2-directed antibody-drug conjugates
20164 citationsauthor #10
Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer
2015158 citationsauthor #10
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
2013193 citationsauthor #2
Abstract 1212: The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo
20121 citationsauthor #2
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
2011328 citationsauthor #12
Abstract 5607: Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab
20107 citationsauthor #1
Abstract S3-6: Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo
20106 citationsauthor #2
223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance
201011 citationsauthor #2
86 Potent anti-tumor activity of T-DM1 antibody–drug conjugate in combination with chemotherapeutic agents in breast tumor cells
20102 citationsauthor #2
Abstract #3239: Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase
20093 citationsauthor #1
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
2009862 citationsauthor #4
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
200982 citationsauthor #6
515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel
20088 citationsauthor #2
A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.
200851 citationsauthor #8

TIMELINE

2008 59 citations

2009 947 citations

2010 26 citations

2011 328 citations

2012 1 citations

2013 193 citations

2015 158 citations

2016 4 citations

2024 35 citations

Carter T. Fields

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT